Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04742595 · ClinicalTrials.gov registry record · Early Phase 1
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
NCT04742595: Completed Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT04742595 is a Early Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04742595, a Early Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This early phase I trial identifies the feasibility, possible benefits and/or side effects of administering SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs) in treating cancer patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the virus responsible for coronavirus disease 2019 (COVID-19). SARS-CoV-2 Specific CTLs are a type of immune cells that are made from donated blood cells grown in the laboratory and are designed to kill cells infected with SARS-CoV-2 virus. Giving CTLs may help control the COVID-19 in cancer patients.
Interventions
- BIOLOGICAL SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2024-09-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04742595
The ClinicalTrials.gov registry entry for NCT04742595 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes is the first listed.
NCT04742595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04742595 about?
NCT04742595 is a clinical study titled "Viral Specific T Cell Therapy for COVID-19 Related Pneumonia". This early phase I trial identifies the feasibility, possible benefits and/or side effects of administering SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs) in treating cancer patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the virus responsible for coronaviru...
What is the current status of trial NCT04742595?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2020-12-18. Estimated completion is 2024-09-20.
What interventions are being tested in trial NCT04742595?
The interventions under investigation include: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT04742595?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.